Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands (DOVE)

This study has been completed.
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Ontario Clinical Oncology Group (OCOG) Identifier:
First received: August 23, 2012
Last updated: September 16, 2015
Last verified: September 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: September 2015
  Primary Completion Date: September 2015 (Final data collection date for primary outcome measure)